ReviewJournal of hematology2026
Luspatercept: From Bench to Bedside and Beyond in the Management of Ineffective Erythropoiesis.
Review in Journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Luspatercept is a novel erythroid maturation agent that has emerged as a significant advancement in the management of ineffective erythropoiesis. By targeting the transforming growth factor-β superfamily signaling pathway, Luspatercept enhances late-stage erythroid differentiation. This review provides an in-depth exploration of its mechanism of action, pharmacologic properties, and clinical efficacy across multiple hematologic disorders. We summarize trial outcomes in lower-risk myelodysplastic syndromes, transfusion-dependent β-thalassemia, and myelofibrosis, highlighting improvements in erythroid response and transfusion independence. The article also discusses adverse event profiles and future directions, including ongoing trials and potential expansion of indications. Luspatercept represents a promising targeted erythroid therapy with benefits across several hematologic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.